PX91 Stock Overview A clinical stage biotechnology company, develops drugs for neurodegenerative diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cassava Sciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cassava Sciences Historical stock prices Current Share Price US$2.86 52 Week High US$38.00 52 Week Low US$2.19 Beta -0.98 1 Month Change -0.59% 3 Month Change -87.51% 1 Year Change -87.01% 3 Year Change -93.07% 5 Year Change -54.44% Change since IPO -98.03%
Recent News & Updates
Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Cassava Sciences, Inc Dec 13
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Nov 26
Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer Nov 19
Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31 Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer
New minor risk - Profitability Aug 14 See more updates
Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Cassava Sciences, Inc Dec 13
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Nov 26
Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer Nov 19
Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31 Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer
New minor risk - Profitability Aug 14
New major risk - Revenue and earnings growth Aug 11
Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member Aug 06
Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials Jul 30 Cassava Sciences, Inc. Announces Chief Executive Officer Changes
New minor risk - Profitability May 17
New major risk - Revenue and earnings growth May 13
New major risk - Share price stability Apr 17
Cassava Sciences, Inc., Annual General Meeting, May 09, 2024 Mar 27
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials Mar 26
New major risk - Revenue and earnings growth Feb 29 Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index
Cassava Sciences, Inc. Announces Board Appointments Dec 08
New major risk - Revenue and earnings growth Nov 08
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease Nov 07
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients Oct 26
New major risk - Share price stability Oct 13
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease Oct 05
Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease Sep 19
Independent Director recently bought €284k worth of stock Aug 24
New major risk - Revenue and earnings growth Aug 04
Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study Jul 06
Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging Jun 28
Independent Director recently bought €2.2m worth of stock Mar 09
Forecast to breakeven in 2023 Mar 03
Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease Feb 09
Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease Jan 25
Cassava Sciences, Inc. Announces Executive Changes Dec 21
Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease Dec 07
Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel Oct 28
Cassava Sciences Announces Initiation of an Open-Label Extension Study Oct 14
Chief Clinical Development Officer recently bought €61k worth of stock Aug 25
Lead Independent Director recently bought €2.0m worth of stock Aug 17
Forecast to breakeven in 2022 Mar 02
Forecast to breakeven in 2022 Nov 12
Cassava Sciences Announces Top-Line Results of 12-Month Interim Analysis from Open-Label Study Evaluating Simufilam in Alzheimer’s Disease Sep 24
Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Cassava Sciences, Inc Sep 03
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease Aug 25
Insufficient new directors Jul 31
No longer forecast to breakeven Jul 21
No longer forecast to breakeven Jul 17 Cassava Sciences, Inc.(NasdaqCM:SAVA) dropped from Russell Microcap Growth Index
Cassava Sciences, Inc. Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release Jun 22
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’S Disease May 12
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam Mar 10
Cassava Sciences, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease Feb 23
Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-Label Study Feb 03
New 90-day high: €10.77 Jan 21
Cassava Sciences, Inc. Appoints James Kupiec as Chief Clinical Development Officer Jan 05
New 90-day low: €5.75 Dec 30
Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’S Disease Nov 06
New 90-day high: €10.37 Oct 08
Independent Director recently bought €1.3m worth of stock Sep 19
New 90-day high - €5.27 Sep 15 Shareholder Returns PX91 DE Pharmaceuticals DE Market 7D 21.6% 3.4% 2.0% 1Y -87.0% -14.7% 9.6%
See full shareholder returns
Return vs Market: PX91 underperformed the German Market which returned 9.1% over the past year.
Price Volatility Is PX91's price volatile compared to industry and market? PX91 volatility PX91 Average Weekly Movement 26.8% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PX91's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PX91's weekly volatility has increased from 21% to 27% over the past year.
About the Company Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Show more Cassava Sciences, Inc. Fundamentals Summary How do Cassava Sciences's earnings and revenue compare to its market cap? PX91 fundamental statistics Market cap €136.69m Earnings (TTM ) -€17.07m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PX91 income statement (TTM ) Revenue US$0 Cost of Revenue US$67.84m Gross Profit -US$67.84m Other Expenses -US$50.17m Earnings -US$17.66m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/07 07:39 End of Day Share Price 2025/01/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cassava Sciences, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Fraser BofA Global Research Mayank Mamtani B. Riley Securities, Inc. Charles Duncan Cantor Fitzgerald & Co.
Show 5 more analysts 
